Medical Services Int’l Poised To Be First Marketer Of Bird Flu Test In China
This article was originally published in The Gray Sheet
Executive Summary
A Canadian diagnostic firm that specializes in developing cost-effective tests for third world countries says it will be the first-to-market in China with a rapid diagnostic test for avian influenza Type A virus, or "bird flu.
You may also be interested in...
Caution on avian flu tests
FDA cautions against relying on "rapid" diagnostic tests for influenza avian flu virus (H5N1) in humans in a document posted on the Office of In Vitro Diagnostic Devices Evaluation & Safety website Nov. 14. "None of the FDA-cleared rapid influenza A tests can differentiate influenza A virus subtypes or discriminate between those subtypes that commonly infect humans and those that typically infect birds," the notice says. Quidel announced Oct. 21 that study results for its QuickVue influenza A+B rapid test suggest it can detect H5N1 (1"The Gray Sheet" Nov. 14, 2005, p. 13). Applied BioSystems has a test designed for research and epidemiological use that reportedly can detect the subtype in less than two hours (2"The Gray Sheet" Nov. 14, 2005, p. 14). The World Health Organization has identified 130 confirmed human cases of avian influenza in Asia since 2003...
Quidel’s Stock Soars In Response To Avian Flu Threat, Gains 22.7% In October
Anticipation of the flu season and the threat of a global pandemic fueled Wall Street's attention on influenza test manufacturer Quidel in October
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”